Table 4.
Clinicopathologic parameters | 3-year RFS | P-value (log-rank) |
---|---|---|
Sex | 0.4376 | |
Male | 0.8640 | |
Female | 0.9630 | |
Age (years) | 0.8146 | |
≤40 | 0.8889 | |
>40 | 0.9305 | |
WBC count (×109/L) | 0.6536 | |
≤5 | 0.9128 | |
>5 | 0.9000 | |
Platelet count (×109/L) | 0.3020 | |
≤40 | 0.8733 | |
>40 | 1.0000 | |
Hemoglobin (g/L) | 0.0895 | |
<100 | 0.9491 | |
≥100 | 0.8125 | |
Induction regimens | 0.2724 | |
ATRA+As2O3+IDA | 1.0000 | |
ATRA+IDA | 0.8908 | |
Maintenance regimens | 0.0159 | |
ATRA+As2O3 | 1.0000 | |
ATRA+chemotherapy | 0.8182 |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; RFS, relapse-free survival; WBC, white blood cell.